Plaintiff Digs Deep In Almay Archives For ‘Hypoallergic’ Fraud Evidence
This article was originally published in The Rose Sheet
Executive Summary
In the absence of FDA regulations, federal courts generally are weighing hypoallergenic false-advertising arguments against the “reasonable consumer” standard, with varying results. However, Almay may have provided a more substantive basis for assessing the truthfulness of its hypoallergenic claims via a letter to FDA on the subject – albeit one from 1973.
You may also be interested in...
Target Cruises Past Hypoallergenic Cosmetic Suit, But Other Defendants On Rockier Road
The plaintiff in a proposed class action against Target Corporation for alleged “hypoallergenic” cosmetic fraud neglected to venture a definition for the term and focused to a distracting extent on claims ultimately found to be non-actionable puffery – e.g., “gentle.” Other hypoallergic suits pending around the US are built on sturdier ground and likely will be harder to dismiss.
Revlon Highlights Flesh Beauty Launch, China Momentum In Q2 Report
The firm remains in brand- and digital-building mode, but it’s seeing marked progress while looking forward to planned H2 innovations and the impact of its recently introduced Flesh line of “inclusive” color cosmetics. Opportunity beckons in China, where Revlon’s second-quarter sales grew 46%.
J&J Scores Early In ‘Hypoallergenic’ Case; Plaintiff’s Definition ‘Implausible,’ Court Says
A California federal judge is more receptive to J&J’s interpretation of “hypoallergenic” – as a term denoting reduced allergy risk compared with other products – than plaintiffs’ ingredient-based definition. Her ruling on the firm’s motion to dismiss differs sharply from a decision earlier this month in the same district concerning Whole Foods hypoallergenic claims, only adding to legal uncertainty.